Agilent to Highlight Digital Pathology Innovations at USCAP 2025
Introduction
Agilent Technologies Inc. is set to showcase its cutting-edge digital pathology solutions at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, scheduled for March 22-27, 2025, in Boston. The company’s participation underscores its commitment to enhancing diagnostic accuracy and efficiency in pathology, particularly through the integration of artificial intelligence (AI) and automated technologies.
Agilent’s Comprehensive Digital Pathology Solutions
Agilent’s digital pathology solutions are designed to revolutionize how tissue samples are analyzed, especially in diagnosing diseases like cancer. The company has partnered with leading organizations including Hamamatsu, PathAI, Proscia, and Visiopharm to develop an end-to-end digital pathology workflow. This advanced solution integrates AI-powered precision pathology software with automated staining technologies, providing laboratories with a comprehensive approach that enhances diagnostic quality and efficiency. From scanning tissue samples to managing data and analyzing images, It’s workflow leverages state-of-the-art technologies to streamline the diagnostic process.
“We are excited to present our digital pathology solutions at USCAP 2025. These innovations are transforming healthcare by ensuring that diagnoses are precise, timely, and reliable,” said Nina Green, Vice President and General Manager of the Clinical Diagnostics Division. “By combining AI-driven technologies with advanced staining methods, we are helping pathologists deliver accurate results faster, facilitating more effective treatment decisions for patients.”
Enhancing Diagnostic Accuracy with AI and Automation
Agilent’s digital pathology solutions emphasize the integration of AI to enhance diagnostic accuracy and efficiency. The AI-driven tools help pathologists by automating the analysis of tissue images, enabling faster, more consistent results. It’s automated tissue staining solutions, which include primary, special, immunohistochemistry (IHC), and in situ hybridization (ISH) staining, ensure that laboratories can deliver consistent, high-quality results while improving productivity. By reducing the time from biopsy to diagnosis, It’s solutions help laboratories meet the increasing demand for faster and more reliable diagnostic workflows.
The company will also showcase key products, such as the Magnis NGS Prep System, which supports next-generation sequencing (NGS) workflows, and the NovoCyte Opteon Spectral Flow Cytometer, a key tool in the analysis of cellular data. These products complement It’s digital pathology suite by offering seamless integration with other laboratory workflows, further enhancing diagnostic efficiency.
Agilent to Highlight Digital Pathology Innovations at USCAP 2025
Live Demonstrations and Interactive Sessions
During USCAP 2025, Agilent will offer live demonstrations of its digital pathology solutions, including tissue scanning, image management, and AI-driven image analysis. These demonstrations will allow attendees to experience firsthand how it’s solutions help pathologists manage large volumes of data, analyze images, and make informed decisions with greater speed and precision. Attendees will also see the benefits of it’s automated tissue staining solutions, which are designed to deliver high-quality, reproducible results with minimal hands-on involvement.
Symposiums at USCAP 2025
Agilent is also hosting two important symposiums during USCAP 2025. The first, titled “Advancing Diagnostics: Cutting-Edge Innovations and Insights in Digital Pathology,” will take place on Monday, March 24, from 12:00–1:00 PM ET. This symposium will feature presentations from leading experts in the field, including Dr. Douglas Clark and Jake Eden from Agilent, Dr. Orly Ardon from Hamamatsu, Dr. Dominique Coco from Proscia, Dr. Anil Parwani from Visiopharm, and Dr. Brian Robinson from PathAI. The symposium will focus on the latest advancements in digital pathology and how these innovations are improving diagnostic workflows.
Additionally, Agilent will host a Medical Affairs Symposium titled “PD-L1 Heterogeneity Across the Patient Journey” on Monday, March 24, from 5:30–7:00 PM ET. Presented by Dr. Matteo Fassan, Professor of Pathology at the University of Padua in Italy, this session will explore the complexities of PD-L1 expression and its implications in cancer diagnosis and treatment.
Conclusion
Agilent’s participation at USCAP 2025 highlights the company’s leadership in advancing digital pathology and its commitment to transforming the way diagnostic labs operate. By integrating AI-driven precision pathology software with automated staining solutions, it is helping pathologists deliver more accurate, timely diagnoses, ultimately improving patient care. Through its innovative solutions and educational symposiums, Agilent aims to further support the pathologist community in enhancing diagnostic workflows and improving patient outcomes.
For more information about these events and Agilent’s pathology solutions, visit the USCAP Agilent booth #512.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive
